156 studies found for:    "Peripheral T-cell lymphoma"
Show Display Options
Rank Status Study
1 Recruiting Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib;   Drug: Pralatrexate;   Drug: Gemcitabine;   Drug: Romidepsin
2 Terminated Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
Conditions: Peripheral T-cell Lymphomas;   Adult T-cell Leukemia;   Adult T-cell Lymphoma;   Peripheral T-cell Lymphoma Unspecified;   Angioimmunoblastic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   T/Null Cell Systemic Type;   Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease
Intervention: Drug: Lenalidomide
3 Active, not recruiting Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: PXD101
4 Not yet recruiting Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Folotyn and Leucovorin;   Drug: Folic Acid;   Drug: Vitamin B12
5 Recruiting Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: GDPT regimen;   Drug: CHOP regimen
6 Completed
Has Results
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
7 Active, not recruiting
Has Results
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Romidepsin
8 Unknown  Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Velcade + ACVBP regimen
9 Recruiting Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Brentuximab vedotin
10 Active, not recruiting Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: KW-0761 (mogamulizumab)
11 Completed CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Alemtuzumab
12 Unknown  Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified);   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma Nasal Type;   Enteropathy- Type T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative);   Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention: Drug: panobinostat and bortezomib
13 Recruiting E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox (E7777)
14 Recruiting Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Pralatrexate injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
15 Active, not recruiting Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Condition: Peripheral T-cell Lymphoma
Intervention:
16 Completed Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: KW-0761
17 Withdrawn A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: E7777
18 Unknown  A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Interventions: Drug: Ontak;   Drug: CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
19 Recruiting Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Romidepsin + CHOP;   Drug: CHOP
20 Completed The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: CHOP regimen alternate with ESHAP regimen;   Drug: Alemtuzumab

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years